TY - JOUR PY - 2016 DA - 2016// TI - 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 JO - Lancet VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)31460-X DO - 10.1016/S0140-6736(16)31460-X ID - ref1 ER - TY - JOUR AU - Fitzmaurice, C. AU - Allen, C. AU - Barber, R. M. PY - 2017 DA - 2017// TI - Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 Cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study JO - Jama Oncol VL - 3 UR - https://doi.org/10.1001/jamaoncol.2016.5688 DO - 10.1001/jamaoncol.2016.5688 ID - Fitzmaurice2017 ER - TY - JOUR AU - Bhatt, J. R. AU - Finelli, A. PY - 2014 DA - 2014// TI - Landmarks in the diagnosis and treatment of renal cell carcinoma JO - Nat Rev Urol VL - 11 UR - https://doi.org/10.1038/nrurol.2014.194 DO - 10.1038/nrurol.2014.194 ID - Bhatt2014 ER - TY - JOUR AU - Amzal, B. AU - Fu, S. AU - Meng, J. AU - Lister, J. AU - Karcher, H. PY - 2017 DA - 2017// TI - Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: a network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma JO - PLoS One VL - 12 UR - https://doi.org/10.1371/journal.pone.0184423 DO - 10.1371/journal.pone.0184423 ID - Amzal2017 ER - TY - JOUR AU - Sheng, X. AU - Chi, Z. AU - Cui, C. PY - 2016 DA - 2016// TI - Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.7395 DO - 10.18632/oncotarget.7395 ID - Sheng2016 ER - TY - JOUR AU - Fernandez-Pello, S. AU - Hofmann, F. AU - Tahbaz, R. PY - 2017 DA - 2017// TI - A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma JO - Eur Urol VL - 71 UR - https://doi.org/10.1016/j.eururo.2016.11.020 DO - 10.1016/j.eururo.2016.11.020 ID - Fernandez-Pello2017 ER - TY - JOUR AU - Gu, W. AU - Zhu, Y. AU - Wang, H. PY - 2015 DA - 2015// TI - Prognostic value of components of body composition in patients treated with targeted therapy for advanced renal cell carcinoma: a retrospective case series JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0118022 DO - 10.1371/journal.pone.0118022 ID - Gu2015 ER - TY - JOUR AU - Zhang, T. AU - Xie, J. AU - Arai, S. PY - 2016 DA - 2016// TI - The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis JO - Oncotarget VL - 7 ID - Zhang2016 ER - TY - JOUR AU - Ribas, A. AU - Wolchok, J. D. PY - 2018 DA - 2018// TI - Cancer immunotherapy using checkpoint blockade JO - Science VL - 359 UR - https://doi.org/10.1126/science.aar4060 DO - 10.1126/science.aar4060 ID - Ribas2018 ER - TY - JOUR AU - Luke, J. J. AU - Ott, P. A. PY - 2015 DA - 2015// TI - PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.2980 DO - 10.18632/oncotarget.2980 ID - Luke2015 ER - TY - JOUR AU - Bamias, A. AU - Escudier, B. AU - Sternberg, C. N. PY - 2017 DA - 2017// TI - Current clinical practice guidelines for the treatment of renal cell carcinoma: a systematic review and critical evaluation JO - Oncologist VL - 22 UR - https://doi.org/10.1634/theoncologist.2016-0435 DO - 10.1634/theoncologist.2016-0435 ID - Bamias2017 ER - TY - JOUR AU - Motzer, R. J. AU - Tannir, N. M. AU - McDermott, D. F. PY - 2018 DA - 2018// TI - Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma JO - New Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1712126 DO - 10.1056/NEJMoa1712126 ID - Motzer2018 ER - TY - JOUR AU - Petrou, P. a. n. a. g. i. o. t. i. s. PY - 2018 DA - 2018// TI - A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer JO - Expert Review of Pharmacoeconomics & Outcomes Research VL - 18 UR - https://doi.org/10.1080/14737167.2018.1439740 DO - 10.1080/14737167.2018.1439740 ID - Petrou2018 ER - TY - JOUR AU - Elbasha, E. H. AU - Chhatwal, J. PY - 2016 DA - 2016// TI - Theoretical foundations and practical applications of within-cycle correction methods JO - Med Decis Mak VL - 36 UR - https://doi.org/10.1177/0272989X15585121 DO - 10.1177/0272989X15585121 ID - Elbasha2016 ER - TY - STD TI - Abdel-Rahman O. Clinical correlates and prognostic value of different metastatic sites in metastatic renal cell carcinoma. Future Oncol. 2017;13(22):1967–80. ID - ref15 ER - TY - JOUR AU - Sarfaty, M. AU - Leshno, M. AU - Gordon, N. PY - 2018 DA - 2018// TI - Cost effectiveness of Nivolumab in advanced renal cell carcinoma JO - Eur Urol VL - 73 UR - https://doi.org/10.1016/j.eururo.2017.07.041 DO - 10.1016/j.eururo.2017.07.041 ID - Sarfaty2018 ER - TY - JOUR AU - Xiao, J. AU - Sun, J. F. AU - Wang, Q. Q. AU - Qi, X. AU - Yao, H. Y. PY - 2017 DA - 2017// TI - Health economic evaluation reporting guideline and application status JO - Zhonghua Yu Fang Yi Xue Za Zhi VL - 51 ID - Xiao2017 ER - TY - JOUR AU - Chouaid, C. h. r. i. s. t. o. s. AU - Luciani, L. a. u. r. a. AU - LeLay, K. a. t. e. l. l. AU - Do, P. a. s. c. a. l. AU - Bennouna, J. a. a. f. a. r. AU - Perol, M. a. u. r. i. c. e. AU - Moro-Sibilot, D. e. n. i. s. AU - Vergnenègre, A. l. a. i. n. AU - de Pouvourville, G. é. r. a. r. d. PY - 2017 DA - 2017// TI - Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR -Mutated Advanced Non–Small Cell Lung Cancers JO - Journal of Thoracic Oncology VL - 12 UR - https://doi.org/10.1016/j.jtho.2017.07.013 DO - 10.1016/j.jtho.2017.07.013 ID - Chouaid2017 ER - TY - JOUR AU - Edwards, S. J. AU - Wakefield, V. AU - Cain, P. PY - 2018 DA - 2018// TI - Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation JO - Health Technol Assess VL - 22 UR - https://doi.org/10.3310/hta22060 DO - 10.3310/hta22060 ID - Edwards2018 ER - TY - JOUR AU - Remak, E. AU - Charbonneau, C. AU - Negrier, S. AU - Kim, S. T. AU - Motzer, R. J. PY - 2008 DA - 2008// TI - Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.13.2662 DO - 10.1200/JCO.2007.13.2662 ID - Remak2008 ER - TY - JOUR AU - Wu, B. AU - Dong, B. AU - Xu, Y. PY - 2012 DA - 2012// TI - Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting JO - PLoS One VL - 7 UR - https://doi.org/10.1371/journal.pone.0032530 DO - 10.1371/journal.pone.0032530 ID - Wu2012 ER - TY - STD TI - US Department of Labor. Calculators. https://www.bls.gov/data/inflation_calculator.htm. Accessed 30 Mar 2018. UR - https://www.bls.gov/data/inflation_calculator.htm ID - ref22 ER - TY - JOUR AU - Tikhonova, I. r. i. n. a. A. AU - Huxley, N. i. c. o. l. a. AU - Snowsill, T. r. i. s. t. a. n. AU - Crathorne, L. o. u. i. s. e. AU - Varley-Campbell, J. o. AU - Napier, M. a. r. k. AU - Hoyle, M. a. r. t. i. n. PY - 2018 DA - 2018// TI - Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England JO - PharmacoEconomics VL - 36 UR - https://doi.org/10.1007/s40273-018-0630-9 DO - 10.1007/s40273-018-0630-9 ID - Tikhonova2018 ER - TY - JOUR AU - McCrea, C. AU - Johal, S. AU - Yang, S. AU - Doan, J. PY - 2018 DA - 2018// TI - Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States JO - Exp Hematol Oncol VL - 7 UR - https://doi.org/10.1186/s40164-018-0095-8 DO - 10.1186/s40164-018-0095-8 ID - McCrea2018 ER - TY - JOUR AU - Akaza, H. AU - Naito, S. AU - Ueno, N. PY - 2015 DA - 2015// TI - Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients JO - Jpn J Clin Oncol VL - 45 UR - https://doi.org/10.1093/jjco/hyv045 DO - 10.1093/jjco/hyv045 ID - Akaza2015 ER - TY - JOUR AU - Meng, Y. a. n. g. AU - Hertel, N. a. d. i. n. e. AU - Ellis, J. o. h. n. AU - Morais, E. d. i. t. h. AU - Johnson, H. e. l. e. n. AU - Philips, Z. o. e. AU - Roskell, N. e. i. l. AU - Walker, A. n. d. r. e. w. AU - Lee, D. a. w. n. PY - 2018 DA - 2018// TI - The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England JO - The European Journal of Health Economics VL - 19 UR - https://doi.org/10.1007/s10198-018-0964-4 DO - 10.1007/s10198-018-0964-4 ID - Meng2018 ER - TY - JOUR AU - Delea, T. E. AU - Amdahl, J. AU - Diaz, J. AU - Nakhaipour, H. R. AU - Hackshaw, M. D. PY - 2015 DA - 2015// TI - Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States JO - J Manag Care Spec Pharm VL - 21 ID - Delea2015 ER - TY - STD TI - RED BOOK Online. 2017. http://www.micromedexsolutions.com/. Accessed 24 Oct 2017. UR - http://www.micromedexsolutions.com ID - ref28 ER - TY - JOUR AU - Hoyle, M. AU - Green, C. AU - Thompson-Coon, J. PY - 2010 DA - 2010// TI - Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma JO - Value Health VL - 13 UR - https://doi.org/10.1111/j.1524-4733.2009.00617.x DO - 10.1111/j.1524-4733.2009.00617.x ID - Hoyle2010 ER - TY - JOUR AU - Benedict, A. AU - Figlin, R. A. AU - Sandstrom, P. PY - 2011 DA - 2011// TI - Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma JO - BJU Int VL - 108 ID - Benedict2011 ER - TY - JOUR AU - Henk, H. J. AU - Chen, C. AU - Benedict, A. AU - Sullivan, J. AU - Teitelbaum, A. PY - 2013 DA - 2013// TI - Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population JO - Clinicoecon Outcomes Res VL - 5 ID - Henk2013 ER - TY - JOUR AU - Perrin, A. AU - Sherman, S. AU - Pal, S. PY - 2015 DA - 2015// TI - Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US JO - J Med Econ VL - 18 UR - https://doi.org/10.3111/13696998.2014.985789 DO - 10.3111/13696998.2014.985789 ID - Perrin2015 ER - TY - JOUR AU - Hansen, R. N. AU - Hackshaw, M. D. AU - Nagar, S. P. PY - 2015 DA - 2015// TI - Health care costs among renal cancer patients using pazopanib and sunitinib JO - J Manag Care Spec Pharm VL - 21 ID - Hansen2015 ER - TY - JOUR AU - Liou, S. Y. AU - Stephens, J. M. AU - Carpiuc, K. T. PY - 2007 DA - 2007// TI - Economic burden of haematological adverse effects in cancer patients: a systematic review JO - Clin Drug Investig VL - 27 UR - https://doi.org/10.2165/00044011-200727060-00002 DO - 10.2165/00044011-200727060-00002 ID - Liou2007 ER - TY - JOUR AU - Amdahl, J. AU - Diaz, J. AU - Sharma, A. PY - 2017 DA - 2017// TI - Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom JO - PLoS One VL - 12 UR - https://doi.org/10.1371/journal.pone.0175920 DO - 10.1371/journal.pone.0175920 ID - Amdahl2017 ER - TY - STD TI - Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–68. ID - ref36 ER - TY - JOUR AU - Isobe, T. AU - Hayashi, M. AU - Tsubata, Y. PY - 2015 DA - 2015// TI - Clinical practice guidelines for the adverse events in medical oncology JO - Nihon Rinsho VL - 73 ID - Isobe2015 ER - TY - JOUR AU - Mickisch, G. AU - Gore, M. AU - Escudier, B. PY - 2010 DA - 2010// TI - Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib JO - Br J Cancer VL - 102 UR - https://doi.org/10.1038/sj.bjc.6605417 DO - 10.1038/sj.bjc.6605417 ID - Mickisch2010 ER - TY - JOUR AU - Jia, Q. PY - 2016 DA - 2016// TI - Cost-effectiveness of durogesic, morphine sulphate controlled-release tablets and oxycontin for advanced cancerous pain JO - Chinese Journal of Clinical Rational Drug Use VL - 9 ID - Jia2016 ER - TY - JOUR AU - Yu-mei, T. AU - Fang-zhan, G. AU - Hong-wu, Z. PY - 2017 DA - 2017// TI - The effectiveness of Chinese herbal fumigation for hand-foot syndrome caused by capecitabine JO - Qinghai Medical Journal VL - 07 ID - Yu-mei2017 ER - TY - JOUR AU - Amdahl, J. AU - Diaz, J. AU - Park, J. AU - Nakhaipour, H. R. AU - Delea, T. E. PY - 2016 DA - 2016// TI - Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada JO - Curr Oncol VL - 23 UR - https://doi.org/10.3747/co.23.2244 DO - 10.3747/co.23.2244 ID - Amdahl2016 ER - TY - JOUR AU - de Groot, S. AU - Redekop, W. K. AU - Versteegh, M. M. PY - 2018 DA - 2018// TI - Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma JO - Qual Life Res VL - 27 UR - https://doi.org/10.1007/s11136-017-1704-4 DO - 10.1007/s11136-017-1704-4 ID - de Groot2018 ER - TY - JOUR AU - Briggs, A. H. AU - Weinstein, M. C. AU - Fenwick, E. A. L. PY - 2012 DA - 2012// TI - Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working Group-6 JO - Medical Decision Making: An International Journal of the Society for Medical Decision Making VL - 32 UR - https://doi.org/10.1177/0272989X12458348 DO - 10.1177/0272989X12458348 ID - Briggs2012 ER - TY - JOUR AU - Tartari, F. AU - Santoni, M. AU - Burattini, L. PY - 2016 DA - 2016// TI - Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges JO - Cancer Treat Rev VL - 48 UR - https://doi.org/10.1016/j.ctrv.2016.06.002 DO - 10.1016/j.ctrv.2016.06.002 ID - Tartari2016 ER - TY - JOUR AU - Hai-tao, C. AU - Jun-qi, W. AU - Yong-xing, S. AU - Baron, A. PY - 2010 DA - 2010// TI - Survey of the advanced Cancer patients′medical costs in registered hospice care agencies in five provinces and municipalities JO - Chinese General Practice VL - 13 ID - Hai-tao2010 ER -